Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last

CNBC
Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last
The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.
Read the full story
This is a short summary. The complete article is published by CNBC.
Continue at CNBC

Headline and summary aggregated from public news feeds. For information only — not financial advice.